Asset Details
Do you wish to reserve the book?
Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
Do you wish to request the book?
Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
2012
Overview
In this trial involving patients with cirrhosis and thrombocytopenia, treatment with eltrombopag before invasive procedures reduced the need for platelet transfusions. More thrombotic events of the portal venous system were observed with eltrombopag than with placebo.
Thrombocytopenia is frequently observed in patients with chronic liver disease, with studies suggesting that it occurs in up to 76% of patients with cirrhosis.
1
–
3
The degree of thrombocytopenia is proportional to the severity of the liver disease.
4
,
5
Thrombocytopenia increases the risk of bleeding during and after invasive procedures and may result in the cancellation or postponement of elective procedures.
6
Platelet transfusions are commonly used to reduce the risk of bleeding during a procedure, but their short duration of efficacy and the risk of transfusion reactions limit their use.
7
,
8
Furthermore, the development of antiplatelet antibodies (alloimmunization) can cause . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Biological and medical sciences
/ Bleeding
/ Elective Surgical Procedures
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Hematologic and hematopoietic diseases
/ Hemorrhage - prevention & control
/ Humans
/ Hydrazines - adverse effects
/ Hydrazines - therapeutic use
/ Liver Cirrhosis - complications
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Male
/ Platelet diseases and coagulopathies
/ Platelet Transfusion - statistics & numerical data
/ Receptors, Thrombopoietin - agonists
/ Receptors, Thrombopoietin - genetics
